GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Vanda Pharmaceuticals Inc. (VNDA) [hlAlert]

Rating:
Buy VNDA
up 5.26 %

Vanda Pharmaceuticals Inc. (VNDA) rated Buy

Posted on: Thursday,  Nov 1, 2007  3:25 PM ET by Friedman Billings

Friedman Billings rated Buy Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on 11/01/2007, when the stock price was $11.39. Since
then, Vanda Pharmaceuticals Inc. has gained 5.27% as of 01/27/2016's recent price of $11.99.
If you would have followed this Friedman Billings's recommendation on VNDA, you would have gained 5.26% of your investment in 3009 days.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

FBR Capital Markets is a full service investment banking, institutional sales, trading and research and asset management firm with a customer-focused and innovative approach to meeting its clients needs. It focuses its banking, advisory, trading and research efforts on seven broad industry sectors including consumer, diversified industrials, energy & natural resources, financial institutions, insurance, real estate and technology, media & telecom. With our headquarters in the Washington, D.C. metropolitan area, our Economic and Washington Policy Analysis groups offer clients a comprehensive overview of national economic trends along with a unique perspective on the impact that legislation and regulation will have on industry sectors and individual companies
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/9/2007 9:25 AM Buy
None
8.94 16.00
as of 8/27/2015
1 Week up  1.01 %
1 Month down  -7.05 %
3 Months up  20.86 %
1 YTD down  -3.38 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/1/2007 3:25 PM Buy
None
11.39 31.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy